Market Research Industry Reports

Benign Prostatic Hyperplasia - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Benign Prostatic Hyperplasia - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H1 2018, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 8, 5, 3, 1, 7, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Benign Prostatic Hyperplasia - Overview
Benign Prostatic Hyperplasia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Benign Prostatic Hyperplasia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
AndroScience Corp
Aphios Corp
Aquestive Therapeutics
Astellas Pharma Inc
BCWorld Pharm Co Ltd
Biolab Farmaceutica Ltda
Chong Kun Dang Pharmaceutical Corp
Curadis GmbH
Dongkook Pharmaceutical Co Ltd
GemVax & KAEL Co Ltd
Health Ever Bio-Tech Co Ltd
Jeil Pharmaceutical Co Ltd
Kissei Pharmaceutical Co Ltd
MEI Pharma Inc
Meiji Seika Pharma Co Ltd
Mezzion Pharma Co Ltd
Nymox Pharmaceutical Corp
Ono Pharmaceutical Co Ltd
OPKO Health Inc
SK Chemicals Co Ltd
Sophiris Bio Inc
Sun Pharma Advanced Research Company Ltd
XuanZhu Pharma Co Ltd
Yuyu Pharma Inc
Benign Prostatic Hyperplasia - Drug Profiles
(alfuzosin hydrochloride ER + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(dutasteride + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(finasteride + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(solifenacin + tamsulosin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(tadalafil + tamsulosin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASC-JM.X2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCWPE-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-1447 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexapotide triflutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KKM-1202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-1AD3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7300243 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-8430506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPK-88004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0131632 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silodosin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sperol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talaporfin sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin hydrochloride DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
topsalysin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-5849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YY-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Benign Prostatic Hyperplasia - Dormant Projects
Benign Prostatic Hyperplasia - Discontinued Products
Benign Prostatic Hyperplasia - Product Development Milestones
Featured News & Press Releases
May 02, 2018: Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco May 20
Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia
Apr 10, 2018: New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology
Mar 22, 2018: FDA Grants Fee Waiver for Tamsulosin DRS New Drug Application
Mar 01, 2018: Symposium and Panel Discussion on Nymox Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3
Feb 05, 2018: Nymox Announces US NDA for Fexapotide for BPH
Jan 30, 2018: Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
Nov 27, 2017: OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy
Nov 13, 2017: Veru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results
Nov 07, 2017: Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana
Oct 13, 2017: Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah
Oct 10, 2017: Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12
Sep 25, 2017: Nymox Announces October 12 Symposium for Companys BPH Drug at American Urological Association Meeting
Sep 15, 2017: Mayne Pharma Adds Urorec (silodosin) Capsules to Its Australian Portfolio
Sep 14, 2017: Nymox Announces New Symposium for Companys BPH Drug at American Urological Association Meeting October 5
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Aquestive Therapeutics, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Astellas Pharma Inc, H1 2018
Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by GemVax & KAEL Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H1 2018
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H1 2018
Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H1 2018
Benign Prostatic Hyperplasia - Dormant Projects, H1 2018
Benign Prostatic Hyperplasia - Dormant Projects, H1 2018 (Contd..1), H1 2018
Benign Prostatic Hyperplasia - Dormant Projects, H1 2018 (Contd..2), H1 2018
Benign Prostatic Hyperplasia - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Global Benign Prostatic Hyperplasia Therapeutics Market Research Report 2018

Benign Prostatic Hyperplasia Therapeutics Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing

USD 2850View Report

Global Benign Prostatic Hyperplasia Devices Market Research Report 2018

Benign Prostatic Hyperplasia Devices Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing

USD 2850View Report

Global Benign Prostatic Hyperplasia Therapeutics Market Research Report 2018

Benign Prostatic Hyperplasia Therapeutics Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing

USD 2850View Report

Global Benign Prostatic Hyperplasia Devices Market Research Report 2018

Benign Prostatic Hyperplasia Devices Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing

USD 2850View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : May 2018
No. of Pages :113
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube